These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

84 related items for PubMed ID: 9484775

  • 1. Oncogenic activation of the PDGF beta receptor by the transmembrane domain of p185neu*.
    Petti LM, Irusta PM, DiMaio D.
    Oncogene; 1998 Feb 19; 16(7):843-51. PubMed ID: 9484775
    [Abstract] [Full Text] [Related]

  • 2. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.
    Zhang HT, O'Rourke DM, Zhao H, Murali R, Mikami Y, Davis JG, Greene MI, Qian X.
    Oncogene; 1998 Jun 04; 16(22):2835-42. PubMed ID: 9671404
    [Abstract] [Full Text] [Related]

  • 3. Specific locations of hydrophilic amino acids in constructed transmembrane ligands of the platelet-derived growth factor beta receptor.
    Freeman-Cook LL, Edwards AP, Dixon AM, Yates KE, Ely L, Engelman DM, Dimaio D.
    J Mol Biol; 2005 Jan 28; 345(4):907-21. PubMed ID: 15588835
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Selection and characterization of small random transmembrane proteins that bind and activate the platelet-derived growth factor beta receptor.
    Freeman-Cook LL, Dixon AM, Frank JB, Xia Y, Ely L, Gerstein M, Engelman DM, DiMaio D.
    J Mol Biol; 2004 May 14; 338(5):907-20. PubMed ID: 15111056
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Physician Education: The Erythropoietin Receptor and Signal Transduction.
    Yoshimura A, Arai K.
    Oncologist; 1996 May 14; 1(5):337-339. PubMed ID: 10388012
    [Abstract] [Full Text] [Related]

  • 8. A 25 kDa polypeptide is the ligand for p185neu and is secreted by activated macrophages.
    Tarakhovsky A, Zaichuk T, Prassolov V, Butenko ZA.
    Oncogene; 1991 Dec 14; 6(12):2187-96. PubMed ID: 1685016
    [Abstract] [Full Text] [Related]

  • 9. Linkage of tyrosine kinase activity with transforming ability of the p185neu oncoprotein.
    Weiner DB, Kokai Y, Wada T, Cohen JA, Williams WV, Greene MI.
    Oncogene; 1989 Oct 14; 4(10):1175-83. PubMed ID: 2571965
    [Abstract] [Full Text] [Related]

  • 10. Intermolecular association and trans-phosphorylation of different neu-kinase forms permit SH2-dependent signaling and oncogenic transformation.
    Qian X, Dougall WC, Fei Z, Greene MI.
    Oncogene; 1995 Jan 05; 10(1):211-9. PubMed ID: 7824275
    [Abstract] [Full Text] [Related]

  • 11. The role of the neu oncogene product in cell transformation and normal development.
    Kokai Y, Wada T, Myers JN, Brown VI, Dobashi K, Cohen J, Hamuro J, Weiner DB, Greene MI.
    Princess Takamatsu Symp; 1988 Jan 05; 19():45-57. PubMed ID: 2908355
    [Abstract] [Full Text] [Related]

  • 12. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.
    Weiner DB, Liu J, Cohen JA, Williams WV, Greene MI.
    Nature; 1989 May 18; 339(6221):230-1. PubMed ID: 2654648
    [Abstract] [Full Text] [Related]

  • 13. Activation of Stat3 preassembled with platelet-derived growth factor beta receptors requires Src kinase activity.
    Wang YZ, Wharton W, Garcia R, Kraker A, Jove R, Pledger WJ.
    Oncogene; 2000 Apr 20; 19(17):2075-85. PubMed ID: 10815799
    [Abstract] [Full Text] [Related]

  • 14. Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly.
    O'Rourke DM, Nute EJ, Davis JG, Wu C, Lee A, Murali R, Zhang HT, Qian X, Kao CC, Greene MI.
    Oncogene; 1998 Mar 05; 16(9):1197-207. PubMed ID: 9528862
    [Abstract] [Full Text] [Related]

  • 15. STAT activation by the PDGF receptor requires juxtamembrane phosphorylation sites but not Src tyrosine kinase activation.
    Sachsenmaier C, Sadowski HB, Cooper JA.
    Oncogene; 1999 Jun 17; 18(24):3583-92. PubMed ID: 10380880
    [Abstract] [Full Text] [Related]

  • 16. Increased mitogenicity of an alphabeta heterodimeric PDGF receptor complex correlates with lack of RasGAP binding.
    Ekman S, Thuresson ER, Heldin CH, Rönnstrand L.
    Oncogene; 1999 Apr 15; 18(15):2481-8. PubMed ID: 10229199
    [Abstract] [Full Text] [Related]

  • 17. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line.
    Ahmed M, Dusanter-Fourt I, Bernard M, Mayeux P, Hawley RG, Bennardo T, Novault S, Bonnet ML, Gisselbrecht S, Varet B, Turhan AG.
    Oncogene; 1998 Jan 29; 16(4):489-96. PubMed ID: 9484838
    [Abstract] [Full Text] [Related]

  • 18. erbB-2/neu transformed rat cholangiocytes recapitulate key cellular and molecular features of human bile duct cancer.
    Lai GH, Zhang Z, Shen XN, Ward DJ, Dewitt JL, Holt SE, Rozich RA, Hixson DC, Sirica AE.
    Gastroenterology; 2005 Dec 29; 129(6):2047-57. PubMed ID: 16344070
    [Abstract] [Full Text] [Related]

  • 19. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo.
    Lofts FJ, Hurst HC, Sternberg MJ, Gullick WJ.
    Oncogene; 1993 Oct 29; 8(10):2813-20. PubMed ID: 8104327
    [Abstract] [Full Text] [Related]

  • 20. v-fps causes transformation by inducing tyrosine phosphorylation and activation of the PDGFbeta receptor.
    Anderson DH, Ismail PM.
    Oncogene; 1998 May 07; 16(18):2321-31. PubMed ID: 9620549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.